natgillin/translations-raw huggingface dataset:
Zykadia has been shown to be effective at treating patients whose disease progressed during or shortly after treatment with crizotinib and who currently have very limited treatment options, as well as patients who have not been treated before. 
Zdravilo Zykadia se je izkazalo za učinkovito pri zdravljenju bolnikov, katerih bolezen je napredovala med zdravljenjem s krizotinibom ali kmalu po njem in ki trenutno nimajo na razpolago veliko možnosti zdravljenja, ter pri zdravljenju bolnikov, ki predhodno še niso bili zdravljeni.
Zykadia is a cancer medicine used on its own to treat adults with a type of lung cancer called nonsmall-cell lung cancer (NSCLC), when the disease is advanced. 
Zykadia je zdravilo, ki se uporablja za zdravljenje odraslih z vrsto pljučnega raka, imenovano nedrobnocelični pljučni rak (NSCLC), pri katerih je bolezen napredovala.
It is only used if the NSCLC is ‘ALKpositive', which means that the cancer cells have certain defects affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase). 
Uporablja se le, če je nedrobnocelični pljučni rak ALK-pozitiven, kar pomeni, da imajo rakave celice določene okvare, ki vplivajo na gen, odgovoren za beljakovino ALK (anaplastična limfomska kinaza).
ALK belongs to a family of proteins called receptor tyrosine kinases, which are involved in the growth of cells and the development of new blood vessels that supply them. 
Anaplastična limfomska kinaza spada v skupino beljakovin, imenovanih receptorji tirozin-kinaze, ki sodelujejo pri rasti celic in razvoju novih krvnih žil, ki te celice oskrbujejo.
Patients given Zykadia lived for an average of 16.6 months without their disease getting worse compared with 8.1 months in patients given standard chemotherapy. 
Bolniki, ki so prejemali zdravilo Zykadia, so živeli povprečno 16,6 meseca brez poslabšanja bolezni, bolniki, ki so prejemali standardno kemoterapijo, pa 8,1 meseca.
Zykadia has been shown to be effective at treating advanced, ALK-positive NSCLC in three main studies in patients whose disease progressed despite previous treatment with the medicine crizotinib: 
Zdravilo Zykadia se je izkazalo za učinkovito pri zdravljenju napredovalega ALK-pozitivnega nedrobnoceličnega pljučnega raka v treh glavnih študijah pri bolnikih, katerih bolezen je napredovala kljub predhodnemu zdravljenju s krizotinibom:
For the full list of side effects and restrictions with Zykadia, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Zykadia glejte navodilo za uporabo.
The active substance in Zykadia, ceritinib, works by blocking the activity of ALK, thereby reducing the growth and spread of the cancer. 
Zdravilna učinkovina v zdravilu Zykadia, ceritinib, deluje tako, da zavira aktivnost anaplastične limfomske kinaze, s čimer zmanjšuje rast in širjenje raka.
In patients with ALK-positive NSCLC, an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion. 
Pri bolnikih z ALK-pozitivnim nedrobnoceličnim pljučnim rakom nastaja nenormalna oblika anaplastične limfomske kinaze, ki rakave celice spodbuja k nenadzorovani delitvi in rasti.
Zykadia contains the active substance ceritinib. 
Zdravilo Zykadia vsebuje učinkovino ceritinib.
Results showed that patients given Zykadia lived for an average of 5.4 months without their disease getting worse (progression-free survival) compared with 1.6 months in patients given standard chemotherapy. 
Rezultati so pokazali, da so bolniki, ki so prejemali zdravilo Zykadia, brez poslabšanja bolezni v povprečju živeli 5,4 meseca, v primerjavi z 1,6 meseca pri tistih, ki so prejemali standardno kemoterapijo.
How does Zykadia work? 
Kako zdravilo Zykadia deluje?
How is Zykadia used? 
Kako se zdravilo Zykadia uporablja?
Zykadia has also been shown to be effective at treating patients who had not been treated before in a study in 376 patients. 
V študiji, v kateri je sodelovalo 376 bolnikov, se je zdravilo Zykadia izkazalo za učinkovito tudi pri zdravljenju bolnikov, ki predhodno še niso bili zdravljeni.
This summary was last updated in March 2018. 
Ta pregled je bil nazadnje posodobljen marca 2018.
The name of the medicine was changed to Sevohale on 29 July 2016. 
Ime zdravila je bilo 29. julija 2016 spremenjeno v Sevohale.
What are the benefits and risks of Sevohale? 
Kakšne so koristi in tveganja zdravila Sevohale?
Further information on Sevohale can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Nadaljnje informacije o zdravilu Sevohale so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Other information about Sevohale 
Druge informacije o zdravilu Sevohale
Sevohale is a general anaesthetic for dogs and cats. 
Zdravilo Sevohale je splošni anestetik za pse in mačke.
The European Medicines Agency concluded that, in accordance with EU requirements, Sevohale has been shown to be comparable to SevoFlo. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Sevohale primerljivo z zdravilom SevoFlo.
Sevocalm received a marketing authorisation valid throughout the EU on 21/06/2016. 
Zdravilo Sevocalm je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 21. junija 2016.
Why is Sevohale authorised in the EU? 
Zakaj je zdravilo Sevohale odobreno v EU?
An overview of Sevohale and why it is authorised in the EU 
Pregled zdravila Sevohale in zakaj je odobreno v EU
The dog or cat breathes in this gas mixture, which causes it to become unconscious. 
Pes ali mačka vdihava to plinsko mešanico, kar povzroči izgubo zavesti.
Sevoflurane mimics the action of GABA, a substance that naturally reduces brain activity, and blocks the action of glutamate, which stimulates the action of the brain. 
Sevofluran posnema delovanje snovi GABA, ki naravno zavira možgansko dejavnost, in zmanjšuje delovanje glutamata, ki spodbuja delovanje možganov.
What is Sevohale and what is it used for? 
Kaj je zdravilo Sevohale in za kaj se uporablja?
Sevohale is given using specialised anaesthetic equipment, usually in a carefully controlled mixture including oxygen. 
Zdravilo Sevohale se daje s pomočjo specializirane opreme za anestezijo, običajno v obliki natančno regulirane plinske mešanice, v kateri je tudi kisik.
Sevohale is a ‘generic medicine'. 
Zdravilo Sevohale je „generično zdravilo“.
Sevohale is used to bring about and maintain general anaesthesia (loss of consciousness). 
Uporablja se za povzročitev in vzdrževanje splošne anestezije (izgube zavesti).
This means that Sevohale contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called SevoFlo. 
To pomeni, da vsebuje enako učinkovino in ima enak način delovanja kot referenčno zdravilo SevoFlo, ki je že odobreno v Evropski uniji (EU).
Safety information has been included in the summary of product characteristics and the package leaflet for Sevohale, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
V povzetek glavnih značilnosti zdravila Sevohale in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
Because Sevohale is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Sevohale generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The precautions are the same as for the reference medicine since Sevohale is a generic medicine. 
Previdnostni ukrepi so enaki kot pri referenčnem zdravilu, saj je zdravilo Sevohale generično zdravilo.
For more information about using Sevohale, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Sevohale glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
1 Previously known as Sevocalm 
1 Prej znano kot zdravilo Sevocalm.
How has Sevohale been studied? 
Kako je bilo zdravilo Sevohale raziskano?
Therefore, the Agency's view was that, as for SevoFlo, the benefits outweigh the identified risks and it can be authorised for use in the EU. 
Zato je agencija menila, da koristi zdravila Sevohale enako kot pri zdravilu SevoFlo odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
How is Sevohale used? 
Kako se zdravilo Sevohale uporablja?
No additional studies were needed as Sevohale is a generic medicine that is given by inhalation and contains the same active substance as the reference medicine, SevoFlo. 
Ker je zdravilo Sevohale generično zdravilo, ki se daje z inhaliranjem in vsebuje enako učinkovino kot referenčno zdravilo SevoFlo, niso bile potrebne nobene dodatne študije.
How does Sevohale work? 
Kako zdravilo Sevohale deluje?
ATCvet code: QI02AA04. 
Oznaka ATC vet: QI02AA04.
Revaccination: every six months. 
Revakcinacija: vsakih 6 mesecev.
The number and type of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label. 
Število in tip sevov, vključenih v končno zdravilo, bosta prilagojena trenutni epidemiološki situaciji v času formulacije končnega zdravila in bosta označena na ovojnini.
These local reactions normally resolve over a period of four weeks post vaccination, but may persist for longer in a small number of animals. 
Te lokalne reakcije običajno izginejo v 4 tednih po cepljenju, lahko pa pri majhnem številu živali vztrajajo dlje.
Use only accordingly to the benefit/risk assessment by the responsible veterinarian. 
Uporabite le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
In some cases ulceration may occur at the injection site. 
V nekaterih primerih se lahko pojavijo ulceracije na mestu injiciranja.
This veterinary medicinal product contains mineral oil. 
Zdravilo vsebuje mineralno olje.
O1 Manisa ................................................................................................................................. ≥ 6 PD50* O1 BFS ....................................................................................................................................... ≥ 6 PD50* O Taiwan 3/97 ........................................................................................................................... ≥ 6 PD50* A22 Iraq ..................................................................................................................................... ≥ 6 PD50* A24 Cruzeiro ............................................................................................................................. ≥ 6 PD50* A Turkey 14/98 ......................................................................................................................... ≥ 6 PD50* Asia 1 Shamir ............................................................................................................................. ≥ 6 PD50* SAT2 Saudi Arabia ................................................................................................................... ≥ 6 PD50* 
O1 Manisa .................................................................................................................................. ≥ 6 ZO50* O1 BFS ....................................................................................................................................... ≥ 6 ZO50* O Taiwan 3/97 ............................................................................................................................ ≥ 6 ZO50* A22 Iraq ...................................................................................................................................... ≥ 6 ZO50* A24 Cruzeiro .............................................................................................................................. ≥ 6 ZO50* A Turkey 14/98 .......................................................................................................................... ≥ 6 ZO50* Asia 1 Shamir ............................................................................................................................. ≥ 6 ZO50* SAT2 Saudi Arabia……………………………………………………………………………≥ 6 ZO50*
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli stranske učinke, tudi tiste ki niso navedeni v tem navodilu za uporabo, ali mislite, da zdravilo ni delovalo, obvestite svojega veterinarja.
Avoid accidental contamination of the vaccine after first broaching and during use. 
Preprečite nenamerno kontaminacijo cepiva po prvem prebadanju in med uporabo.
Each dose of 2 ml of emulsion contains: 
Vsak odmerek (2 ml) emulzije vsebuje:
Schedule should be adjusted accordingly (see section 4.9). 
Razpored cepljenja je zato potrebno ustrezno prilagoditi (glejte poglavje 4.9).
Date of first authorisation: 15/07/2013 Date of last renewal: 14/06/2018 
Datum zadnjega podaljšanja dovoljenja za promet: 14/06/2018
Do not mix the vaccine by vigorous shaking because it leads to entrapment of air bubbles. 
Cepiva ne mešajte z močnim tresenjem, ker to lahko povzroči nastanek zračnih mehurčkov.
The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of foot-and-mouth disease. 
Uporaba tega zdravila za uporabo v veterinarski medicini je dovoljena z zakonodajo Evropske skupnosti le pod posebnimi pogoji v skladu z ukrepi za nadzor nad slinavko in parkljevko.
Pigs: 4 weeks after vaccination. 
Prašiči: 4 tedne po cepljenju.
Schedule should be adjusted accordingly (see section “dosage”). 
Razpored cepljenja je zato potrebno ustrezno prilagoditi (glejte poglavje »Odmerjanje«).
Merial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest FRANCE 
Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest Francija
Cattle and sheep: 7 days after vaccination. 
Govedo in ovce: 7 dni po cepljenju.
Polypropylene bottle with a nitrile elastomer closure and sealed with an aluminium cap. 
Polipropilenska steklenička z nitrilelastomerno zaporko in zapečatena z aluminijastim pokrovčkom.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake EXP.
In cattle, the antibody levels measured were above those shown to be protective. 
Pri govedu je nivo izmerjenih protiteles nad tistim, ki je dokazano zaščitni.
Following repeated administration at short intervals, the intensity of these reactions may be increased. 
Po večkratnem dajanju v kratkih časovnih intervalih se lahko intenziteta teh reakcij poveča.
10 doses 25 doses 50 doses 100 doses 150 doses 10 x 10 doses 10 x 25 doses 10 x 50 doses 10 x 100 doses 10 x 150 doses 
1 x 10 odmerki 1 x 25 odmerki 1 x 50 odmerki 1 x 100 odmerki 1 x 150 odmerki 10 x 10 odmerki 10 x 25 odmerki 10 x 50 odmerki 10 x 100 odmerki 10 x 150 odmerki
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
The safety of the veterinary medicinal product has not been established during lactation. 
Varnost zdravila v obdobju laktacije ni bila ugotovljena.
White emulsion after shaking. 
Bela emulzija po pretresanju.
When animals have to be vaccinated in presence of maternal antibodies, revaccination at 8-10 weeks is recommended. 
V primeru da je potrebno živali cepiti ob prisotnosti maternalnih protiteles, je priporočljiva revakcinacija pri 8-10 tednih.
Maternal antibodies may interfere with vaccination. 
Maternalna protitelesa lahko motijo nastanek imunosti.
Major incompatibilities: Do not mix with any other veterinary medicinal product. 
Glavne inkompatibilnosti: Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini.
For the full list of excipients, see section 6.1. 
Pomožne snovi: Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
* PD50 - 50% protective dose in cattle as described in Ph. Eur. 
*ZO50 - 50% zaščitnega odmerka pri govedu, kot določa Ph. Eur monografija 0063.
Pigs: IM. 
Prašiči: IM
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 
Zato se za uporabo tega imunološkega zdravila pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera od primera.
one dose of 2 ml, by subcutaneous route. 
en odmerek po 2 ml, subkutano
Pharmaceutical group: inactivated viral vaccine, foot-and-mouth disease virus. 
Farmakoterapevtska skupina: Inaktivirana virusna cepiva, virus slinavke in parkljevke.
- in cattle following administration of a double dose followed by a single dose 7 weeks later and a third vaccination with a single dose 13 weeks after the second dose, - in sheep following administration of a double dose followed by a single dose 5 weeks later and a third vaccination with a single dose 7 weeks after the second dose, - in pigs following administration of a double dose followed by a single dose 3 weeks later and a third vaccination with a single dose 7 weeks after the second dose. 
- pri govedu po dajanju dvakratnega odmerka in enega odmerka 7 tednov kasneje in tretjim cepljenjem z enim odmerkom 13 tednov po drugem cepljenju, - pri ovcah po dajanju dvakratnega odmerka in enega odmerka 5 tednov kasneje in tretjim cepljenjem z enim odmerkom 7 tednov po drugem cepljenju, - pri prašičih po dajanju dvakratnega odmerka in enega odmerka 3 tedne kasneje in tretjim cepljenjem z enim odmerkom 7 tednov po drugem cepljenju.
When very young pigs (at 2 weeks old) have to be vaccinated, revaccination at 8-10 weeks is recommended. 
Če je potrebno cepiti zelo mlade pujske (pri 2 tednih starosti), je priporočljiva revakcinacija pri 8-10 tednih.
Primary vaccination: Cattle from 2 weeks of age: 
Osnovno cepljenje: Govedo od 2 tednov starosti dalje:
50 doses 100 doses 150 doses 
100 odmerkov 150 odmerkov
Swellings (diameter of up to 12 cm in ruminants and 4 cm in pigs) occurred very commonly in most animals after administration of a dose of vaccine. 
Oteklina (premera do 12 cm pri prežvekovalcih in 4 cm pri prašičih) se je po cepljenju z enim odmerkom cepiva zelo pogosto pojavila pri večini živali.
Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml. 
Inaktivirani antigeni v cepivu so prečiščeni in ne vsebujejo dovolj ne-strukturnih proteinov (NSP), da bi izzval odziv protiteles po dajanju trivalentnega cepiva, ki vsebuje količino antigena ki ustreza vsaj 15 ZO50 na posamezni sev na 2 ml odmerek.
A slight increase of rectal temperature of up to 1.2 °C for 4 days post-vaccination with no other generalised clinical signs is commonly observed. 
Pogosto se pri živalih po cepljenju pojavi zmerno povečanje rektalne temperature za do 1,2 °C, ki traja 4 dni po cepljenju brez drugih generaliziranih kliničnih znakov.
Do not warm the product before use. 
Pred uporabo cepiva ne grejte.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated ) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. 
Ni podatkov o varnosti ter učinkovitosti ob uporabi tega imunološkega zdravila s katerim koli drugim zdravilom za uporabo v veterinarski medicini.
Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: 
Največ tri od spodaj navedenih prečiščenih, inaktiviranih sevov virusa slinavke in parkljevke:
Vaccination of cattle with strains O1 Manisa, O1 BFS, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia1 Shamir and SAT2 Saudi Arabia resulted in a reduction of clinical signs in animals exposed to infection. 
S študijami je dilo dokazano, da cepljenje goveda s sevi O1 Manisa, O1 BFS, A22 Iraq; A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir in SAT2 Saudi Arabia, dokazano zmanjša pojavnost kliničnih znakov pri živalih, izpostavljenih okužbi.
No antibodies to NSP were detected using the PrioCHECK FMDV NS test kit: 
Z uporabo PrioCHECK FMDV NS testa niso bila zaznana protitelesa proti NSP:
Pigs: for intramuscular use. 
Prašiči: intramuskularno.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV 10 odmerkov
Following repeated administration at short intervals, the intensity and frequency of these reactions may be increased. 
Po večkratnem dajanju v kratkih časovnih intervalih se lahko intenziteta teh reakcij povečal.
EU/2/13/153/001- 850 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/13/153/001- 850
EU/2/13/153/001-850 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/13/153/001-850
Homogenize the content of the vial by gentle mixing before the insertion of needle. 
Homogenizirajte vsebino stekleničke z nežnim tresenjem pred prebadanjem z iglo.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC BIOLOŠKIH UČINKOVIN IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
Shelf life of the veterinary medicinal product not containing strain Asia1 Shamir as packaged for sale: 6 months. 
Rok uporabnosti zdravila, ki ne vsebuje seva Asia1 Shamir, v pakiranju za prodajo: 6 mesecev.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs 
PRILOGA II A. PROIZVAJALEC BIOLOŠKIH UČINKOVIN IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
Zero days. 
Karenca: Nič dni.
Shelf life of the veterinary medicinal product containing strain Asia1 Shamir as packaged for sale: 2 months. 
Rok uporabnosti zdravila, ki vsebuje sev Asia1 Shamir, v pakiranju za prodajo: 2 meseca.
Duration of immunity: vaccination of cattle, sheep and pigs induced the production of neutralising antibodies that persisted for at least 6 months. 
Trajanje imunosti: cepljenje goveda, ovc in prašičev inducira nastanek nevtralizacijskih protiteles, ki vztrajajo vsaj 6 mesecev.
Liquid paraffin 537 mg. White emulsion after shaking. 
Tekoči parafin 537 mg.
10 doses 25 doses 
25 odmerkov
FMD antigen ≥ 6 PD50 per strain 
KOLIČINA UČINKOVIN(E) FMD antigen ≥ 6 PD50 na sev
Sodium chloride Potassium dihydrogen phosphate Potassium chloride Disodium phosphate anhydrous Potassium hydroxide Water for injections. 
6.1 Seznam pomožnih snovi parafin, tekoči manid monooleat polisorbat 80 trometamol natrijev klorid kalijev dihidrogenfosfat kalijev klorid natrijev hidrogenfosfat, brezvodni kalijev hidroksid voda za injekcije
Pigs from 2 weeks of age: 
Prašiči od 2 tednov starosti dalje: